-
Retatrutide and the Grey Market: Buyer Beware
This should go without saying, but the internet can be both an incredible resource and an extremely dangerous place for health and wellness information. At a time when obesity rates are soaring, mental and emotional stress are at an all-time high, and access to reputable healthcare can feel nearly impossible, many people are turning online in search of solutions. Unfortunately, that desperation leaves individuals vulnerable to the predatory promises of the wellness industry. The latest example is the buzz around retatrutide; or “Reta,” as it’s trending on TikTok. Like candy offered from the back of a van, it’s tempting, accessible,…
-
How GLP-1s Are Reshaping Consumer Behavior
It’s been about a month since FNCE 2025 in Nashville, and I’m still sifting through my notes and revisiting the sessions I loved. One that stood out was the panel “The GLP-1 Effect: Understanding Consumer Behavior Shifts and Their Impact on Food, Nutrition, and Innovation.” The sheer scale of GLP-1 adoption and the depth of the data presented were striking. What made the session even more compelling was its interdisciplinary perspective, bringing together insights from industry leaders, physicians, RDs, and AI-generated consumer modeling. GLP-1 medications are reshaping metabolic health, culture, consumer expectations, and the future of the food landscape. Here…
-
What’s the Deal with GLP-1 Microdosing?
Is Less Really More? When it comes to GLP-1 medications like Ozempic and Wegovy, that’s the question more providers and patients are starting to ask. Originally approved for type 2 diabetes and later for obesity treatment, GLP-1 and other incretin-based therapies have rapidly gained traction in both clinical and consumer spaces. If you’re newer to prescribing or supporting GLP-1 therapy, I’ve put together a four-part series covering key considerations, including initiation, weight management, cost, and side effect mitigation. Now, a new conversation is emerging: GLP-1 microdosing. What does microdosing mean in this context? Does it have clinical merit? And who…
-
Obesity Care vs. Weight Loss: What’s the Difference?
The International Obesity Collaborative, a global alliance of professional organizations focused on improving obesity care, recently released a powerful consensus statement: obesity care and weight loss are not the same. You might be wondering: What’s the difference? Isn’t all obesity care centered around weight loss? And wouldn’t weight loss be appropriate for someone with obesity? The answer may surprise you. Let’s take a closer look at the International Obesity Collaborative’s new consensus statement, what it means for healthcare professionals, and how it could reshape the way we approach obesity treatment in clinical practice.
-
Dizziness and Wegovy: What’s the Connection?
I’ve recently had an increasing number of patients report dizziness while taking Wegovy (semaglutide). This has been observed in both newly prescribed patients and those who have been on the medication for over a year. The dizziness appears distinct from more common side effects such as nausea, vomiting, diarrhea, and constipation. It occurs suddenly and unpredictably but is consistently present. What could be causing this dizziness in patients using Wegovy for weight loss? Let’s explore the science to better understand this phenomenon. What is Wegovy? Wegovy is a once weekly prescription medication containing semaglutide, which is used for chronic weight…
